Compare Citius Pharmaceuticals Inc (CTXR) vs EOG Resources Inc (EOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs EOG Resources Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while EOG Resources Inc trades at $148.8 (market cap $77.90B). The key difference: EOG Resources Inc is far larger — about 5719.5× Citius Pharmaceuticals Inc's market cap, and EOG Resources Inc pays a 2.75% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and EOG Resources Inc for 59 Days on average.
| CTXR | EOG | |
|---|---|---|
Market Cap | $13.62M | $77.90B |
Volume | 132,438 | 2,930,386 |
Sector | Health | Energy |
52-Week High | $1.82 | $153.74 |
52-Week Low | $0.48 | $101.78 |
Typical Hold Time | 17 Days | 59 Days |
Enterprise Value | $3.79M | $81.24B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
EOG Resources trades at $148.16, up 2.74% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 25.81% net income margin and consistent earnings beats, though revenue declined to $22.58B in 2025. Recent CFO transition and upcoming Q3 earnings on November 6, 2026 are key developments. Technical indicators show the stock trading near pivot point resistance at $148 with RSI suggesting potential overbought conditions.
EOG presents a compelling value opportunity with attractive valuation multiples (P/E 11.56, EV/EBITDA 5.84) and strong analyst support (59% buy rating, $164.77 target). Risks include oil price volatility and recent insider selling. The company's disciplined capital allocation and 5% oil volume growth guidance support long-term upside potential despite near-term revenue pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
